Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.76 EUR | -2.59% |
|
+1.58% | 0.00% |
Jul. 11 | Knight Therapeutics Announced Normal Course Issuer Bid | MT |
Jul. 11 | Knight Therapeutics Brief: Announcing Normal Course Issuer Bid | MT |
Sales 2024 * | 346M 254M 233M | Sales 2025 * | 356M 261M 240M | Capitalization | 584M 428M 393M |
---|---|---|---|---|---|
Net income 2024 * | 2M 1.47M 1.35M | Net income 2025 * | 13M 9.53M 8.75M | EV / Sales 2024 * | 1.69 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.64 x |
P/E ratio 2024 * |
200
x | P/E ratio 2025 * |
56.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.54% |
Latest transcript on Knight Therapeutics Inc.
1 week | -1.57% | ||
Current month | -0.53% | ||
1 month | -4.57% | ||
3 months | -3.59% |
![Extreme 3.72](/images/extremecours_fleche.png)
![Extreme 3.64](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 13-10-31 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 16-06-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 14-01-05 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Robert Lande
BRD | Director/Board Member | 61 | 12-12-31 |
Date | Price | Change |
---|---|---|
24-07-12 | 3.76 | -2.59% |
24-07-11 | 3.86 | +1.58% |
24-07-10 | 3.8 | +1.60% |
24-07-09 | 3.74 | -2.60% |
24-07-08 | 3.84 | +0.52% |
Delayed Quote Börse Stuttgart, July 12, 2024 at 02:14 pm EDT
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.04% | 72.48B | |
+31.10% | 10.32B | |
+37.94% | 4.82B | |
-17.33% | 4.59B | |
+21.49% | 3.72B | |
+24.92% | 2.21B | |
-36.84% | 1.88B | |
-43.31% | 1.8B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- 04K Stock